

Publications

Richter B, **Arnolds S**, Worth H, Berger M. Management of acute asthma in an emergency department, a general and an "asthma unit".
European Respiratory Journal 5, Suppl.15: 1424, 1992

Arnolds SA, Richter B, Mertens PR, Berger M. Untersuchung zur Qualitätssicherung der stationären Behandlung notfallmäßig eingewiesener Asthmatiker.
Rheinisch-Westfälische Gesellschaft für Innere Medizin. 159. Tagung, Düsseldorf, 4. und 5. Dezember 1992

Wöller W, Kruse J, **Arnolds S**, Kraut D, Richter B, Worth H. Negative cortisone attitude in patients with bronchial asthma (Article in German).
Pneumologie46 (8): 326-329, 1992

Wöller W, Kruse J, Reister G, Winter P, Richter B, **Arnolds S**, Kraut D. Cortisone level and emotional support by key figures in patients with bronchial asthma (Article in German).
Psychother Psychosom Med Psychol 43 (5): 171-177, 1993

Arnolds S, Berger M. Buchkapitel „Die Zuckerkrankheit“ für den Themenband Mensch und Gesundheit des Bertelsmann-Lexikon-Verlages, 1993

Renner R, Berger W, **Hirschberger S**, Kuglin B, Pramming S. Blutzuckerregulation während der Nacht bei Typ-I-diabetischen Patienten: Insulin Semilente MC versus Monotard HM.
Diabetes und Stoffwechsel 6, Suppl. 1: 58, 1997

Rave K, Heise T, Weyer C, Herrnberger J, Bender R, **Hirschberger S**, Heinemann L. Metabolische Effekte von i.m. vs. S.c. injiziertem Normalinsulin und Insulin lispro.
Diabetes und Stoffwechsel 7, Suppl. 1: 119, 1998

Rave K, Heise T, Weyer C, Herrnberger J, Bender R, **Hirschberger S**, Heinemann L. Intramuscular vs. subcutaneous injection of regular insulin and insulin lispro: comparison of the metabolic effects in healthy subjects.
Diabetes 47, Suppl. 1: 1377 (A356), 1998

Rave K, Heise T, Weyer C, Herrnberger J, Bender R, **Hirschberger S**, Heinemann L. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
Diabetic Medicine 15: 747-751, 1998

Sinha K, Weyer C, Loftager M, **Hirschberger S**, Heise T, Heinemann L. Time-action profile of the soluble, fatty acid acylated long-acting insulin analogue NN304.
Diabetologia 41, Suppl. 1: 188 (A 49), 1998

Herrnberger J, Heise T, Rave K, Bender R, **Hirschberger S**, Heinemann L. Metabolic effects of i.m. vs. S.c. injection of soluble insulin and insulin lispro in healthy subjects.
Diabetologia 41, Suppl. 1: 961 (A 248), 1998

Bott U, Ebrahim S, Leukel P, **Hirschberger S**, Sieber H-J. Effekt des Insulinanalogons Insulin Aspart auf Lebensqualität und Therapiezufriedenheit bei Patienten mit Typ-1-Diabetes.

Diabetes und Stoffwechsel 8, Suppl. 1: 12, 1999

Bott U, Ebrahim S, **Hirschberger S**, Leukel P, Sieber J. Effect of the rapid acting insulin analogue insulin aspart on quality-of-life and treatment satisfaction in type 1 diabetic patients.

Diabetes 48, Suppl. 1: 0481, 1999

Brunner GA, **Hirschberger S**, Sendlhofer G, Wutte A, Ellmerer M, Schaupp L, Krejs GJ, Pieber TR. Prandial glycemia with subcutaneous injection of insulin aspart after the meal in type 1 diabetic patients.

Diabetes 48, Suppl. 1: 0425, 1999

Brunner GA, Sendlhofer G, Wutte A, Ellmerer M, Soegaard B, Siebenhofer A, **Hirschberger S**, Krejs GJ, Pieber TR. Pharmacokinetic and pharmacodynamic properties of insulin analog NN304 in comparison to NPH insulin in humans.

Diabetes 48, Suppl. 1: 04440, 1999

Kimmerle R, Heinemann L, Heise T, Bender R, Weyer C, **Hirschberger S**, Berger M. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.

Menopause 6: 36-42, 1999

Heinemann L, Sinha C, Weyer C, Loftager M, **Hirschberger S**, Heise T. Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304.

Diabetic Medicine 16: 332-338, 1999

Rave K, Heise T, Clauson P, **Hirschberger S**, Heinemann L. Wirkung des β_3 -Adrenorezeptor Agonisten UL-TG 307 auf die Insulinsensitivität bei Typ-II-Diabetikern.

Diabetes und Stoffwechsel 8, Suppl. 1: 71, 1999

Rave K, Heise T, Clauson P, **Hirschberger S**, Heinemann L. Effects of the β_3 -adrenoreceptor agonist UL-TG 307 on insulin sensitivity and insulin secretion in type 2 diabetic patients.

Diabetes 48, Suppl. 1: 0486, 1999

Rave K, Heise T, Clauson P, **Hirschberger S**, Heinemann L. Lack of effects of the β_3 -adrenoreceptor agonist UL-TG 307 on insulin sensitivity and insulin secretion in type 2 diabetic patients.

Exp Clin Endocrinol Diabetes 107 :442-446, 1999

Brunner GA, **Hirschberger S**, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs GJ, Pieber TR. Post-prandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus.

Diabet Med 17: 371-375, 2000

Brunner GA, Sendlhofer G, Wutte A, Ellmerer M, Sogaard B, Siebenhofer A, **Hirschberger S**, Krejs GJ, Pieber TR. Pharmacokinetic and pharmacodynamic

properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.

Exp Clin Endocrinol Diabetes 108: 100-105, 2000

Bretzel RG, Medding J, **Hirschberger S**, Linn T. Insulin aspart efficacy and safety compared to human soluble insulin and human premix insulin (30/70) in patients with type 2 diabetes mellitus. Diabetologia 44, Suppl. 1: 804, 2001

Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, **Hirschberger S**, Pieber TR. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 25: 2053-2057, 2002

Nosek L, Heinemann L, Kaiser M, **Arnolds S**, Heise T. No increase in the duration of action with rising doses of insulin aspart. Diabetes und Stoffwechsel 12, Suppl. 1: V-109, 2003

Nosek L, Heinemann L, Kaiser M, **Arnolds S**, Heise T. No increase in the duration of action with rising doses of insulin aspart. Diabetes 52, Suppl. 1: 551-P, 2003

Bott U, Ebrahim S, **Hirschberger S**, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with type 1 diabetes. Diabet Med 20: 626-634, 2003

Bretzel G, **Arnolds S**, Medding J, Linn T. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care 27: 1023-1027, 2004

Arnolds S, Heise T. Neue Formen der Insulinapplikation: Inhalatives Insulin, orales Insulin. Der Diabetologe 2: 332-339, 2006

Arnolds S, Kapitza C, Heise T. Buchkapitel „Therapiemöglichkeiten mit GLP-1-Analoga und Inkretinmimetika“ für das Buch „GLP-1 als Therapieprinzip bei Typ 2-Diabetes – Inkretinmimetika und DPP-4-Inhibitoren“. UNI-MED SCIENCE 2. Auflage: 73-86, 2006

Müller UA, Hunger-Dathe W, Müller N, Lodwig V, Langen L, **Arnolds S** und das Advisory Board Insulinpumpentherapie für Erwachsene. Langzeithglykämie und Hypoglykämien nach Teilnahme am strukturierten Behandlungs- und Schulungsprogramm „Insulinpumpen-Therapie für erwachsene Patienten mit Diabetes mellitus Typ 1“ von Roche Diagnostics GmbH. Diabetologie 2007; 2: 161-168, 2007

Arnolds S, Heise T. Inhaled insulin. Best Pract Res Clin Endocrinol Metab 21 (4): 555-571, 2007

Arnolds S, Rave K. Basal insulin glargine vs prandial insulin lispro in type 2 diabetes. Lancet; 372: 370-371, 2008

Arnolds S, Dellweg S, Clair J, Dain M-P, Nauck MA, Rave K, Kapitza C. Insulin glargine (GLAR) + metformin (MET): an efficacious and safe regimen that can be

combined with exenatide (EXE) or sitagliptin (SITA). *Diabetes*; 58, Suppl. 1: A141, 2009

Arnolds S, Rave K, Hövelmann U, Fischer A, Sert-Langeron C, Heise T. Insulin glulisine has a faster onset of action than insulin aspart. *Diabetes*; 58, Suppl. 1: A141, 2009

Sha S, Devineni D, Ghosh A, Hompesch M, **Arnolds S**, Morrow L, Spitzer H, Blake J, Wexler DB, Tan Y, Smulders K, Demariest K, Rothenberg PL. JNJ-28431754/TA-7284, a novel sodium glucose co-transporter (SGLT) inhibitor: safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) in patients with type 2 diabetes (T2DM). *Diabetes* 58, Suppl. 1: A95, 2009

Arnolds S, Dellweg S, Clair J, Dain M-P, Nauck MA, Rave K, Kapitza C. Further improvement in postprandial glucose control when adding exenatide (EXE) or sitagliptin (SITA) to combination therapy with insulin glargine (GLAR) and metformin (MET) – a proof-of-concept study. *Diabetes Care*; 33: 1509-1511, 2010

Arnolds S, Rave K, Hövelmann U, Fischer A, Sert-Langeron C, Heise T. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. *Exp Clin Endocrinol Diabetes* 2010 [Epub ahead of Print]. DOI <http://dx.doi.org/10.1055/s-0030-1252067>.

Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, **Arnolds S**, Morrow L, Spitzer H, Blake J, Wexler D, Tan Y, Smulders K, Demarest K, Rothenburg PL. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, improved glucose control in subjects with type 2 diabetes and was well tolerated. *Diabetes* 59, Suppl 1: A155, 2010

Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic (PK/PD) principles pave the way for optimal basal insulin therapy in type 2 diabetes. *Int J Clin Pract* 10.1111/J.1742-1241.2010.02470.x